GlobeNewswire: Cotinga Pharmaceuticals Inc. Contains the last 10 of 25 releaseshttp://www.globenewswire.com/External?Length=42024-03-29T12:57:13ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2019/07/18/1884815/0/en/Cotinga-Pharmaceuticals-Releases-Additional-Interim-Data-of-Phase-1b-2a-Combination-Trial-of-COTI-2-in-Solid-Tumors.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmaceuticals Releases Additional Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors2019-07-18T16:40:33Z<![CDATA[Cohort 3 fully enrolled Cohort 3 fully enrolled]]>https://www.globenewswire.com/news-release/2019/06/27/1875533/0/en/Cotinga-Pharmaceuticals-Doses-First-Patient-in-Third-Cohort-of-Phase-1b-2a-Combination-Trial-of-COTI-2-in-Solid-Tumors.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmaceuticals Doses First Patient in Third Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors2019-06-27T16:18:11Z<![CDATA[TORONTO and BOSTON, June 27, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, announced today that the Company has commenced dosing patients in the third cohort of its ongoing Phase 1b/2a clinical trial of COTI-2 plus cisplatin in solid tumors. The objective of the third cohort is to continue to evaluate the safety and tolerability of COTI-2 in combination with standard-of-care cisplatin.]]>https://www.globenewswire.com/news-release/2019/06/05/1864853/0/en/Cotinga-Pharmaceuticals-Announces-Initiation-of-Next-Cohort-of-Phase-1b-2a-Combination-Trial-of-COTI-2-in-Solid-Tumors.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmaceuticals Announces Initiation of Next Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors2019-06-05T16:42:28Z<![CDATA[Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased dose Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased dose]]>https://www.globenewswire.com/news-release/2019/06/04/1864346/0/en/Cotinga-Pharmacueticals-Announces-Closing-of-Second-Tranche-of-Unit-Offering.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmacueticals Announces Closing of Second Tranche of Unit Offering2019-06-04T22:01:36Z<![CDATA[TORONTO and BOSTON, June 04, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective June 4, 2019 (the “Closing Date”), it completed, for gross proceeds of $100,000, a second tranche offering (the “Offering”) of units (“Units”) comprised of $100,000 of senior secured debentures (the “Debentures”) and 1,000,000 non-transferable common share purchase warrants exercisable at $0.10 per Warrant to arm’s length lenders and a lender who is a director and officer of the Company (the “Subscribers”). The Company intends to use the proceeds from the Offering to fund the initiation of both COTI-2 combination trials (one in solid tumors with cisplatin and the other in triple negative breast cancer with eribulin) and for general operations as well as corporate purposes.]]>https://www.globenewswire.com/news-release/2019/05/22/1841195/0/en/Cotinga-Pharmacueticals-Announces-Closing-of-Unit-Offering.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmacueticals Announces Closing of Unit Offering2019-05-22T21:26:02Z<![CDATA[TORONTO and BOSTON, May 22, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical stage biopharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that effective May 22, 2019 (the “Closing Date”), it completed, for gross proceeds of $199,970, an offering (the “Offering”) of units (“Units”) comprised of $199,970 of senior secured debentures (the “Debentures”) and 1,999,700 non-transferable common share purchase warrants exercisable at $0.10 per Warrant to arm’s length lenders and a lender who is a director of the Company (the “Subscribers”). The Company intends to use the proceeds from the Offering to fund the initiation of both COTI-2 combination trials (one in solid tumors with cisplatin and the other in triple negative breast cancer with eribulin) and for general operations as well as corporate purposes.]]>https://www.globenewswire.com/news-release/2019/05/08/1819580/0/en/Cotinga-Pharmaceuticals-Releases-Early-Interim-Data-of-Phase-1b-2a-Combination-Trial-of-COTI-2-in-Solid-Tumors.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmaceuticals Releases Early Interim Data of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors2019-05-08T15:10:39Z<![CDATA[Cohort two fully enrolled in a wide range of cancer types Cohort two fully enrolled in a wide range of cancer types]]>https://www.globenewswire.com/news-release/2019/04/05/1797799/0/en/Cotinga-Pharmaceuticals-Reports-Fiscal-2019-Third-Quarter-Financial-and-Operating-Results.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmaceuticals Reports Fiscal 2019 Third Quarter Financial and Operating Results2019-04-05T17:18:17Z<![CDATA[TORONTO and BOSTON, April 05, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT; OTCQB: COTQF) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, reported its financial and operating results today for the three and nine months ended January 31, 2019. Recent highlights include:]]>https://www.globenewswire.com/news-release/2019/03/19/1757224/0/en/Cotinga-Pharmacueticals-Provides-Scientific-and-Business-Update-at-Annual-General-Meeting-and-Announces-Unit-Offering.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmacueticals Provides Scientific and Business Update at Annual General Meeting and Announces Unit Offering 2019-03-19T15:00:00Z<![CDATA[Highlighted progress and continued commitment to advancing the clinical development of lead asset COTI-2 in multiple oncology indications Highlighted progress and continued commitment to advancing the clinical development of lead asset COTI-2 in multiple oncology indications]]>https://www.globenewswire.com/news-release/2019/02/26/1742721/0/en/Cotinga-Pharmaceuticals-Doses-First-Patient-in-Second-Cohort-of-Phase-1b-2a-Combination-Trial-of-COTI-2-in-Solid-Tumors.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmaceuticals Doses First Patient in Second Cohort of Phase 1b/2a Combination Trial of COTI-2 in Solid Tumors2019-02-26T16:08:38Z<![CDATA[Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased dose Independent Dose Escalation Committee (DEC) recommends continuing the study at an increased dose]]>https://www.globenewswire.com/news-release/2019/01/29/1707004/0/en/Cotinga-Pharmaceuticals-Doses-Cohort-1-Patients-With-Combination-Therapy-in-Phase-1b-2a-Trial-of-COTI-2.html?f=22&fvtc=4&fvtv=46874Cotinga Pharmaceuticals Doses Cohort 1 Patients With Combination Therapy in Phase 1b/2a Trial of COTI-22019-01-29T15:21:02Z<![CDATA[TORONTO and BOSTON, Jan. 29, 2019 (GLOBE NEWSWIRE) -- Cotinga Pharmaceuticals Inc. (TSX Venture: COT) (“Cotinga” or the “Company”), a clinical-stage pharmaceutical company advancing a pipeline of targeted therapies for the treatment of cancer, today announced that it has dosed the first cohort of patient with COTI-2 in combination with standard of care chemotherapy in its ongoing Phase 1b/2a trial.]]>